"OpportunityAnalyzer: Genital Herpes - Opportunity Analysis and Forecasts to 2023" Published

Genital herpes (GH) is a life-long viral infection of the genitalia and urogenital tract. It is one of the most common sexually transmitted infections (STIs) and is a leading cause of genital ulcers around the world. Patients with GH can suffer from recurring episodes of symptom outbreaks, which usually involve painful ulcerations. The prevalence of GH in the seven major pharmaceutical markets (7MM) covered in this report (US, France, Germany, Italy, Spain, UK, and Japan) has been increasing, and GH is beginning to be viewed as a significant global public health problem, especially because the infection can assist the transmission of human immunodeficiency virus 1 (HIV-1).

There is currently no effective preventative vaccine or cure for GH, and the treatment landscape is dominated by generic nucleoside analogues. Despite the effectiveness of these drugs in managing the symptoms in the majority of patients, the lack of treatment alternatives and the shortcomings of the current treatments have stimulated investments in new treatment options for this vast patient population.

Full Report Details at
- http://www.fastmr.com/prod/1058674_opportunityanalyzer_genital.aspx?afid=302

For the purposes of this report, GlobalData defines the GH market to include sales of GH-specific medication in patients 18 years and older. GlobalData expects the market to experience moderate growth that is primarily driven by the uptake of novel therapies - led by Agenus's HerpV and Genocea's GEN-003 - in the US and 5EU (France, Germany, Italy, Spain and UK).

Highlights

Key Questions Answered

* Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the GH marketplace. Will the leading pipeline agents fulfil these unmet needs during the forecast period (2013-2023)?
* What research and development (R&D) strategies will companies leverage to compete in the future GH marketplace?
* Which patient population(s) are most likely to be targeted for GH -specific product development?
* What clinical and commercial factors are likely to influence GH uptake in the US, 5EU and Japan?

Key Findings

* GlobalData projects the GH market in the US, 5EU and Japan to grow from approximately $490m in 2013 to $668m in 2023, at a compound annual growth rate (CAGR) of 3.1%. This growth across the 7MM will primarily be driven by the launch of pipeline agents, especially the therapeutic vaccines in the US and 5EU, while continued generic erosion across the 7MM, particularly in the 5EU and Japan, is expected to curtail market growth over the forecast period.
* While pipeline agents have the potential to address some of the unmet needs in the GH treatment, available data do not demonstrate that they will be able to fully address these issues, according to interviewed KOLs.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023
- OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018
- EpiCast Report: Genital Herpes - Epidemiology Forecast to 2023
- OpportunityAnalyzer: Celiac Disease - Opportunity Analysis and Forecast to 2023
- PharmaPoint: Alzheimer's Disease - Global Drug Forecast and Market Analysis to 2023